Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

ImmVira Starts China/US Phase II Trial of Oncolytic Virus Therapy for Cancer

publication date: Jun 14, 2021

ImmVira of Shenzhen has dosed the first patients in a China/US Phase II trial of its lead drug, an oncolytic virus product. MVR-T3011 is a proprietary next-gen, genetically modified oncolytic herpes simplex virus (oHSV) delivered to the tumor.  It was developed on a novel virus backbone design that was driven by ImmVira's insights into oncolytic viruses and recombinant gene expertise. In its Phase I trials, MVR-T3011 showed promising safety and efficacy. It will be tested in solid tumors and melanoma. More details....

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes


Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital